Conexeu Sciences is an early-stage medical device company developing CXU, a temperature-responsive collagen-based extracellular matrix scaffold. CXU is delivered as a liquid at room temperature and transitions into a gel-like scaffold at body temperature to fit irregular wound geometries and promote tissue remodeling. Conexeu is currently in preclinical development and has not yet received regulatory clearance. The strategy for Conexeu is to obtain FDA 510(k) clearance for wound care, specifically targeting acute wounds and burns, followed by a pilot commercial launch in burn units and trauma wards. The Conexeu business model involves expanding the CXU platform into additional clinical applications, including injectable fillers for medical aesthetics, dental soft-tissue regeneration, veterinary care, and 3D bioprinting. While Conexeu intends to seek reimbursement for wound care, Conexeu also focuses on entering cash-pay markets like aesthetics and dentistry to avoid reimbursement complexities. Conexeu holds assigned patents in several jurisdictions covering the composition and methods of use for CXU gelation technology. Conexeu relies on third-party contract manufacturing organizations to scale production as Conexeu moves toward planned regulatory submissions and commercial entry.